Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 12/2013

01-12-2013 | Original Article

Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma

Authors: Eun-Seok Choi, Seung-Gyun Ha, Han-Soo Kim, Jae Hong Ha, Jin Chul Paeng, Ilkyu Han

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 12/2013

Login to get access

Abstract

Purpose

Preoperative identification of aggressiveness is important for the establishment of a treatment strategy in patients with soft-tissue sarcoma (STS). We compared the predictive values of various metabolic parameters derived from PET/CT with 18F-FDG, including maximal standardized uptake value (SUVmax), total lesion glycolysis (TLG) and metabolic tumour volume (MTV).

Methods

A total of 66 patients with STS who had undergone FDG PET/CT before tumour resection were reviewed retrospectively. We determined SUVmax, TLG and MTV to compare their value in predicting disease progression, which was defined as local recurrence and metastases. Receiver operating characteristic curve (ROC) analysis was used to compare the accuracy. Univariate and multivariate analyses of conventional clinicopathological variables were used to compare the reliability of the metabolic parameters.

Results

TLG exhibited greater accuracy than SUVmax or MTV in ROC analysis (area under curve, AUC, 0.802, 0.726 and 0.681, respectively). The cut-off values for disease progression derived from the AUC data were TLG 250; SUVmax 6.0, and MTV 40 cm3. In univariate analysis, TLG (>250) was a more significant predictive factor than SUVmax and MTV (P < 0.001, P = 0.031 and P = 0.022, respectively). TLG was the only meaningful metabolic parameter in the multivariate analysis (P = 0.008) other than presence of metastasis at diagnosis (P = 0.003).

Conclusion

TLG is a more accurate predictor of disease progression than SUVmax or MTV. TLG enables accurate preoperative assessment of aggressiveness comparable with conventional clinicopathological parameters.
Literature
2.
go back to reference Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002;20:791–6.PubMedCrossRef Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002;20:791–6.PubMedCrossRef
4.
go back to reference Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A, Willeke F, Cardona S, Mechtersheimer G, et al. Prognostic significance of preoperative [18-F]fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg. 2005;241:286–94.PubMedCrossRef Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A, Willeke F, Cardona S, Mechtersheimer G, et al. Prognostic significance of preoperative [18-F]fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg. 2005;241:286–94.PubMedCrossRef
5.
go back to reference Benz MR, Allen-Auerbach MS, Eilber FC, Chen HJ, Dry S, Phelps ME, et al. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med. 2008;49:1579–84. doi:10.2967/jnumed.108.053694.PubMedCrossRef Benz MR, Allen-Auerbach MS, Eilber FC, Chen HJ, Dry S, Phelps ME, et al. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med. 2008;49:1579–84. doi:10.​2967/​jnumed.​108.​053694.PubMedCrossRef
6.
go back to reference Fuglo HM, Jorgensen SM, Loft A, Hovgaard D, Petersen MM. The diagnostic and prognostic value of (18)F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients. Eur J Nucl Med Mol Imaging. 2012;39:1416–24. doi:10.1007/s00259-012-2159-z.PubMedCrossRef Fuglo HM, Jorgensen SM, Loft A, Hovgaard D, Petersen MM. The diagnostic and prognostic value of (18)F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients. Eur J Nucl Med Mol Imaging. 2012;39:1416–24. doi:10.​1007/​s00259-012-2159-z.PubMedCrossRef
7.
go back to reference Akhurst T, Ng V, Larson SM, O'Donoghue JA, O'Neel J, Erdi Y, et al. Tumor burden assessment with positron emission tomography with [18-F] 2-fluoro 2-deoxyglucose (FDG PET) modeled in metastatic renal cell cancer. Clin Positron Imaging. 2000;3:57–65. Akhurst T, Ng V, Larson SM, O'Donoghue JA, O'Neel J, Erdi Y, et al. Tumor burden assessment with positron emission tomography with [18-F] 2-fluoro 2-deoxyglucose (FDG PET) modeled in metastatic renal cell cancer. Clin Positron Imaging. 2000;3:57–65.
8.
go back to reference Bastiaannet E, Groen H, Jager PL, Cobben DC, van der Graaf WT, Vaalburg W, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev. 2004;30:83–101. doi:10.1016/j.ctrv.2003.07.004.PubMedCrossRef Bastiaannet E, Groen H, Jager PL, Cobben DC, van der Graaf WT, Vaalburg W, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev. 2004;30:83–101. doi:10.​1016/​j.​ctrv.​2003.​07.​004.PubMedCrossRef
9.
go back to reference Eary JF, O'Sullivan F, Powitan Y, Chandhury KR, Vernon C, Bruckner JD, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging. 2002;29:1149–54. doi:10.1007/s00259-002-0859-5.PubMedCrossRef Eary JF, O'Sullivan F, Powitan Y, Chandhury KR, Vernon C, Bruckner JD, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging. 2002;29:1149–54. doi:10.​1007/​s00259-002-0859-5.PubMedCrossRef
10.
go back to reference Folpe AL, Lyles RH, Sprouse JT, Conrad 3rd EU, Eary JF. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000;6:1279–87.PubMed Folpe AL, Lyles RH, Sprouse JT, Conrad 3rd EU, Eary JF. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000;6:1279–87.PubMed
11.
go back to reference Im HJ, Kim TS, Park SY, Min HS, Kim JH, Kang HG, et al. Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma. Eur J Nucl Med Mol Imaging. 2012;39:39–49. doi:10.1007/s00259-011-1936-4.PubMedCrossRef Im HJ, Kim TS, Park SY, Min HS, Kim JH, Kang HG, et al. Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma. Eur J Nucl Med Mol Imaging. 2012;39:39–49. doi:10.​1007/​s00259-011-1936-4.PubMedCrossRef
13.
go back to reference Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2:159–71.PubMedCrossRef Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2:159–71.PubMedCrossRef
14.
go back to reference Biehl KJ, Kong FM, Dehdashti F, Jin JY, Mutic S, El Naqa I, et al. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate? J Nucl Med. 2006;47:1808–12.PubMed Biehl KJ, Kong FM, Dehdashti F, Jin JY, Mutic S, El Naqa I, et al. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate? J Nucl Med. 2006;47:1808–12.PubMed
17.
go back to reference Chung HH, Kwon HW, Kang KW, Park NH, Song YS, Chung JK, et al. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. Ann Surg Oncol. 2012;19:1966–72. doi:10.1245/s10434-011-2153-x.PubMedCrossRef Chung HH, Kwon HW, Kang KW, Park NH, Song YS, Chung JK, et al. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer. Ann Surg Oncol. 2012;19:1966–72. doi:10.​1245/​s10434-011-2153-x.PubMedCrossRef
18.
go back to reference Rakheja R, Makis W, Skamene S, Nahal A, Brimo F, Azoulay L, et al. Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients. AJR Am J Roentgenol. 2012;198:1409–16. doi:10.2214/AJR.11.7560.PubMedCrossRef Rakheja R, Makis W, Skamene S, Nahal A, Brimo F, Azoulay L, et al. Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients. AJR Am J Roentgenol. 2012;198:1409–16. doi:10.​2214/​AJR.​11.​7560.PubMedCrossRef
19.
go back to reference Schulte M, Brecht-Krauss D, Heymer B, Guhlmann A, Hartwig E, Sarkar MR, et al. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible? Eur J Nucl Med. 1999;26:599–605.PubMedCrossRef Schulte M, Brecht-Krauss D, Heymer B, Guhlmann A, Hartwig E, Sarkar MR, et al. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible? Eur J Nucl Med. 1999;26:599–605.PubMedCrossRef
Metadata
Title
Total lesion glycolysis by 18F-FDG PET/CT is a reliable predictor of prognosis in soft-tissue sarcoma
Authors
Eun-Seok Choi
Seung-Gyun Ha
Han-Soo Kim
Jae Hong Ha
Jin Chul Paeng
Ilkyu Han
Publication date
01-12-2013
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 12/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-013-2511-y

Other articles of this Issue 12/2013

European Journal of Nuclear Medicine and Molecular Imaging 12/2013 Go to the issue